Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-07 4:09 pm Sale | 2024-12-31 | 13G | Atossa Therapeutics, Inc. ATOS | CVI Investments, Inc. | 5,662,500 4.300% | -2,100,000 (-27.05%) | Filing History |
| 2024-11-12 1:32 pm Unchanged | 2024-09-30 | 13G | Atossa Therapeutics, Inc. ATOS | The Vanguard Group | 6,598,296 5.240% | 0 (Unchanged) | Filing History |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | Atossa Therapeutics, Inc. ATOS | BlackRock Inc. BLK | 9,667,615 7.700% | 0 (Unchanged) | Filing History |
| 2024-11-04 11:27 am Purchase | 2024-09-30 | 13G | Atossa Therapeutics, Inc. ATOS | The Vanguard Group | 6,598,296 5.240% | 900,760 (+15.81%) | Filing History |
| 2024-10-22 3:24 pm Purchase | 2024-09-30 | 13G | Atossa Therapeutics, Inc. ATOS | BlackRock Inc. BLK | 9,667,615 7.700% | 6,078,932 (+169.39%) | Filing History |
| 2023-02-09 11:07 am Sale | 2022-12-30 | 13G | Atossa Therapeutics, Inc. ATOS | The Vanguard Group | 5,697,536 4.500% | -1,273,314 (-18.27%) | Filing History |
| 2022-07-08 4:57 pm Sale | 2022-06-30 | 13G | Atossa Therapeutics, Inc. ATOS | BlackRock Inc. BLK | 3,588,683 2.800% | -5,950,910 (-62.38%) | Filing History |
| 2022-02-14 3:16 pm Purchase | 2021-12-31 | 13G | Atossa Therapeutics, Inc. ATOS | CVI Investments, Inc. | 7,762,500 5.800% | 3,962,500 (+104.28%) | Filing History |
| 2022-02-09 3:24 pm Purchase | 2021-12-31 | 13G | Atossa Therapeutics, Inc. ATOS | The Vanguard Group | 6,970,850 5.510% | 6,970,850 (New Position) | Filing History |
| 2022-02-04 4:12 pm Purchase | 2021-12-31 | 13G | Atossa Therapeutics, Inc. ATOS | BlackRock Inc. BLK | 9,539,593 7.500% | 9,539,593 (New Position) | Filing History |
| 2022-01-13 10:36 am Sale | 2021-12-31 | 13G | Atossa Therapeutics, Inc. ATOS | Empery Asset Management, LP | 1,312,500 1.030% | -3,448,000 (-72.43%) | Filing History |
| 2021-01-15 4:09 pm Purchase | 2020-01-06 | 13G | Atossa Therapeutics, Inc. ATOS | Mitchell P. Kopin | 3,749,923 4.990% | 1,499,923 (+66.66%) | Filing History |
| 2021-01-15 11:42 am Purchase | 2021-01-06 | 13G | Atossa Therapeutics, Inc. ATOS | CVI Investments, Inc. | 3,800,000 5.300% | 1,495,711 (+64.91%) | Filing History |
| 2021-01-15 11:41 am Purchase | 2020-12-31 | 13G | Atossa Therapeutics, Inc. ATOS | CVI Investments, Inc. | 2,304,289 4.900% | 179,289 (+8.44%) | Filing History |
| 2021-01-14 09:00 am Purchase | 2021-01-06 | 13G | Atossa Therapeutics, Inc. ATOS | Empery Asset Management, LP | 4,760,500 5.320% | 4,760,500 (New Position) | Filing History |
| 2020-12-28 06:14 am Purchase | 2020-12-17 | 13G | Atossa Therapeutics, Inc. ATOS | Mitchell P. Kopin | 2,250,000 4.900% | 2,150,032 (+2150.72%) | Filing History |
| 2020-12-18 12:01 pm Purchase | 2020-12-09 | 13G | Atossa Therapeutics, Inc. ATOS | CVI Investments, Inc. | 2,125,000 8.500% | 2,125,000 (New Position) | Filing History |